JPRN-UMIN000048446招募中未知
The impact of switching to two-drug antiretroviral therapy on body weight and metabolic profiles: A randomized, open-label, two-parallel-group, multicenter trial. - The impact of switching to 2-drug antiretroviral therapy on body weight and metabolic profiles.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Individuals with active opportunistic illnesses. 2)Any history of detection of major NRTI or INSTI mutations. 3)Any history of virologic failure (HIV-1 RNA >200 copies/mL) for which salvage therapy were required. 4)Individuals who had failed to HIV pre-exposure prophylaxis (PrEP). 5)Individuals with untreated syphilis (or until 7 days after completion of the treatment of syphilis). 6)PWH with creatine clearance of <30 mL/min/1.73m2, liver cirrhosis, malignancy, or use of cancer chemotherapeutic/immunosuppressive agents. 7)PWH with ALT >= 5 times the upper limit of normal (ULN), ALT >= 3 times ULN, and bilirubin >= 1.5 times ULN. 8)PWH with HBV infection (positive for HBsAg or HBV-DNA), history of nucleos(t)ide analogue therapy for HBV, or history of chronic HBV infection. 9)Individuals who receive or anticipate receiving treatment for hepatitis C during the study period. 10)Individuals who receive insulin therapy, SGLT-2 inhibitor, or GLP-1 receptor agonist.
研究者
相似试验
终止
4 期
NNRTI/PI Toxicity Switch to Darunavir StudyHIVNCT00765154St Stephens Aids Trust12
已完成
3 期
Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125HIVNCT00792324St Stephens Aids Trust24
进行中（未招募）
4 期
Investigating if switching HIV patients from stable combined antiretroviral therapy to Delstrigo has fewer unwanted side effects e.g. weight gain, while being just as effective at maintaining an undetectable HIV viral loadHuman immunodeficiency virus-1 (HIV-1)Infections and InfestationsHuman immunodeficiency virus [HIV] diseaseISRCTN42856592Chelsea and Westminster Hospital NHS Foundation Trust60
进行中（未招募）
1 期
Antiretroviral treatment with maraviroc plus ritonavir-boosted darunavir for early salvage therapyAdult patients with HIV-1 infection that present virologic failure to first-line antiretroviral treatment.MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-003501-10-ESVall d'Hebron Institut de Recerca (VHIR)90
已完成
不适用
Pharmacokinetic Interaction between Antiretroviral and Cytotoxic therapy in HIV-infected patients - a pilot studyHuman Immunodeficiency Virus (HIV)1002531910047438lymphomaNL-OMON37346Onze Lieve Vrouwe Gasthuis10